TW202237647A - 狼瘡發作之治療 - Google Patents
狼瘡發作之治療 Download PDFInfo
- Publication number
- TW202237647A TW202237647A TW110137117A TW110137117A TW202237647A TW 202237647 A TW202237647 A TW 202237647A TW 110137117 A TW110137117 A TW 110137117A TW 110137117 A TW110137117 A TW 110137117A TW 202237647 A TW202237647 A TW 202237647A
- Authority
- TW
- Taiwan
- Prior art keywords
- patient
- patients
- sle
- anilumab
- baseline
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Lubricants (AREA)
- Glass Compositions (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089355P | 2020-10-08 | 2020-10-08 | |
| US63/089,355 | 2020-10-08 | ||
| US202163178748P | 2021-04-23 | 2021-04-23 | |
| US63/178,748 | 2021-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202237647A true TW202237647A (zh) | 2022-10-01 |
Family
ID=78269610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110137117A TW202237647A (zh) | 2020-10-08 | 2021-10-06 | 狼瘡發作之治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240026015A1 (https=) |
| EP (1) | EP4225791A1 (https=) |
| JP (1) | JP2023546361A (https=) |
| KR (1) | KR20230082659A (https=) |
| CN (1) | CN116406296A (https=) |
| AU (1) | AU2021356122B2 (https=) |
| BR (1) | BR112023006328A2 (https=) |
| CA (1) | CA3197055A1 (https=) |
| IL (1) | IL301759A (https=) |
| TW (1) | TW202237647A (https=) |
| WO (1) | WO2022074123A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20231255T1 (hr) | 2021-04-23 | 2024-02-02 | Astrazeneca Ab | Režim doziranja anti-ifnar1 za potkožnu injekciju |
| BR112023021868A2 (pt) * | 2021-04-23 | 2023-12-19 | Astrazeneca Ab | Tratamento de lúpus eritematoso cutâneo |
| EP4587005A1 (en) | 2022-09-14 | 2025-07-23 | Viatris Asia Pacific Pte. Ltd. | Sip 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases |
| EP4545090A1 (en) * | 2023-10-27 | 2025-04-30 | Universität Leipzig | Interferon-a receptor immune modulator for use as a medicament |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE035082T2 (en) | 2004-06-21 | 2018-05-02 | Squibb & Sons Llc | Interferon alpha receptor 1 antibodies and their use |
| EP2687232A1 (en) * | 2006-12-06 | 2014-01-22 | MedImmune, LLC | Methods of treating systemic lupus erythematosus |
| HRP20160855T1 (hr) | 2008-02-08 | 2016-09-23 | Medimmune, Llc | Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda |
| US20120251546A1 (en) | 2009-09-03 | 2012-10-04 | Medimmune Llc | Type 1 inteferon diagnostic |
| CA2995222C (en) | 2015-08-19 | 2021-07-13 | Medimmune, Llc | Stable anti-ifnar1 formulation |
| CN106243226B (zh) * | 2016-08-05 | 2019-02-12 | 北京智仁美博生物科技有限公司 | 抗人ifnar1的抗体及其用途 |
| KR102766960B1 (ko) * | 2019-11-11 | 2025-02-11 | 아스트라제네카 아베 | 전신성 홍반성 루푸스에서 i형 인터페론 억제 |
| CN115667309A (zh) * | 2020-05-29 | 2023-01-31 | 阿斯利康(瑞典)有限公司 | 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病 |
-
2021
- 2021-10-06 TW TW110137117A patent/TW202237647A/zh unknown
- 2021-10-07 US US18/248,280 patent/US20240026015A1/en active Pending
- 2021-10-07 KR KR1020237015211A patent/KR20230082659A/ko active Pending
- 2021-10-07 WO PCT/EP2021/077702 patent/WO2022074123A1/en not_active Ceased
- 2021-10-07 AU AU2021356122A patent/AU2021356122B2/en active Active
- 2021-10-07 CA CA3197055A patent/CA3197055A1/en active Pending
- 2021-10-07 BR BR112023006328A patent/BR112023006328A2/pt unknown
- 2021-10-07 JP JP2023521356A patent/JP2023546361A/ja active Pending
- 2021-10-07 EP EP21794319.0A patent/EP4225791A1/en active Pending
- 2021-10-07 IL IL301759A patent/IL301759A/en unknown
- 2021-10-07 CN CN202180068143.4A patent/CN116406296A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023006328A2 (pt) | 2023-05-09 |
| AU2021356122A1 (en) | 2023-06-08 |
| CA3197055A1 (en) | 2022-04-14 |
| KR20230082659A (ko) | 2023-06-08 |
| IL301759A (en) | 2023-05-01 |
| CN116406296A (zh) | 2023-07-07 |
| US20240026015A1 (en) | 2024-01-25 |
| AU2021356122B2 (en) | 2026-02-05 |
| WO2022074123A1 (en) | 2022-04-14 |
| EP4225791A1 (en) | 2023-08-16 |
| JP2023546361A (ja) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7805393B2 (ja) | 皮下注射のための抗ｉｆｎａｒ１投薬計画 | |
| AU2021356122B2 (en) | Treatment of flares in lupus | |
| US20250002591A1 (en) | Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythermatosus patients | |
| TW202340245A (zh) | 狼瘡之治療 | |
| TW202430212A (zh) | 狼瘡之治療 | |
| EA052183B1 (ru) | Лечение кожной красной волчанки | |
| HK40087032B (en) | Anti-ifnar1 dosing regime for subcutaneous injection | |
| HK40087032A (en) | Anti-ifnar1 dosing regime for subcutaneous injection | |
| EP4713361A1 (en) | Treatment of lupus | |
| CN117677638A (zh) | 狼疮的治疗 | |
| CN117337305A (zh) | 系统性红斑狼疮患者中的1型干扰素受体抑制剂类固醇节制 | |
| CN117157099A (zh) | 用于皮下注射的抗ifnar1给药方案 | |
| EA047082B1 (ru) | Схема введения дозы антитела к ifnar 1 для подкожной инъекции |